Breaking News

Odyssey Health Selects Syneos to Support Concussion Treatment Trial

Will provide a regulatory review for the clinical development plans for Odyssey's concussion drug ONP-002 and novel intranasal device.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Odyssey Health, Inc., a company focused on developing life-enhancing medical products, has selected Syneos Health, a biopharmaceutical services organization to support its Investigational New Drug (IND) Application. Odyssey Health is developing a pharmaceutical treatment for mild Traumatic Brain Injury (mTBI).    Odyssey’s lead candidate for concussion, ONP-002 has completed a Phase I safety trial and the company submitted a pre-IND application to the FDA and received instructive feedbac...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters